Sarepta Therapeutics Inc (SRPT)
118.60
-1.82
(-1.51%)
USD |
NASDAQ |
Nov 08, 10:06
Sarepta Therapeutics Revenue (Annual): 1.243B for Dec. 31, 2023
Revenue (Annual) Chart
Historical Revenue (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 1.243B |
December 31, 2022 | 933.01M |
December 31, 2021 | 701.89M |
December 31, 2020 | 540.10M |
December 31, 2019 | 380.83M |
December 31, 2018 | 301.03M |
December 31, 2017 | 154.58M |
December 31, 2016 | 5.421M |
December 31, 2015 | 1.253M |
December 31, 2014 | 9.757M |
December 31, 2013 | 14.22M |
December 31, 2012 | 37.33M |
December 31, 2011 | 46.99M |
December 31, 2010 | 29.42M |
Date | Value |
---|---|
December 31, 2009 | 17.58M |
December 31, 2008 | 21.26M |
December 31, 2007 | 10.99M |
December 31, 2006 | 0.1153M |
December 31, 2005 | 4.784M |
December 31, 2004 | 0.4305M |
December 31, 2003 | 0.9699M |
December 31, 2002 | 0.8368M |
December 31, 2001 | 0.7061M |
December 31, 2000 | 1.297M |
December 31, 1999 | 0.10M |
December 31, 1998 | 0.10M |
December 31, 1997 | 0.10M |
December 31, 1996 | 0.10M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Annual) Range, Past 5 Years
380.83M
Minimum
2019
1.243B
Maximum
2023
759.83M
Average
701.89M
Median
2021
Revenue (Annual) Benchmarks
Regenxbio Inc | 90.24M |
Catalyst Pharmaceuticals Inc | 398.20M |
Vertex Pharmaceuticals Inc | 9.869B |
Entrada Therapeutics Inc | 129.01M |
Edgewise Therapeutics Inc | -- |